Clinical Trial Detail

NCT ID NCT02861300
Title CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Case Comprehensive Cancer Center
Indications

colorectal cancer

Advanced Solid Tumor

Therapies

Capecitabine + Telaglenastat

Age Groups: adult senior

Additional content available in CKB BOOST